China Biotechs Race To Get First Global IO Green Light Within Months
Multiple US Fast-Track Reviews Underway
Within months, one of the three latest immuno-oncology drugs from Chinese firms Innovent, Junshi and Akeso is likely to be approved, providing new competition to global giants such as BMS and Merck & Co. as they race each other over to the finish line.
You may also be interested in...
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.